Latest Breaking News On - Laurie stelzer - Page 1 : vimarsana.com

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesLaurie stelzerJeffrey albersMarkc mckennaColitis organisationResearch development assetExchange commissionCompany seriesa preferred stockPrometheus biosciences incCompany board of directorsDevelopment pipeline overviewCompany quarterly reports on formSpyre therapeutics incSpyre therapeuticsCameron turtleChief executive officer

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJeffrey albersLaurie stelzerMarkc mckennaCompany seriesa preferred stockCompany board of directorsDevelopment pipeline overviewPrometheus biosciences incSpyre therapeutics incColitis organisationResearch development assetCompany quarterly reports on formExchange commissionSpyre therapeuticsChief executive officerChief executive

Aeglea BioTherapeutics Changes Name To Spyre Therapeutics; To Begin Trading Under Symbol SYRE

(RTTNews) - Aeglea BioTherapeutics, Inc. (AGLE) announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, .

Jeffrey albersLaurie stelzerEidos therapeutics incAeglea biotherapeutics incSpyre therapeutics incStrategy bio pharma incSpyre therapeuticsCameron turtleChief operating officerChief strategy officerBridgebio pharmaChief business officerEidos therapeutics

Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News By Reuters

Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News By Reuters
investing.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investing.com Daily Mail and Mail on Sunday newspapers.

France generalLaurie stelzerMirati therapeuticsBloomberg newsChief executive officer david meek

Sanofi to explore acquisition of cancer drugmaker Mirati- Bloomberg News

Deliberations are ongoing and there is no certainty they will result in an agreement, the report said, adding that Mirati could also attract interest from other suitors. A Sanofi spokesperson responded to a Reuters' request saying the company does not comment on market rumors. Mirati, whose shares rose about 40% to $60, also said it does not comment on market rumors or speculation.

France generalSriparna royLaurie stelzerShilpi majumdarMirati therapeuticsBloomberg newsChief executive officer david meek